摘要
目的:比较分析两种亚胺培南/西司他丁钠制剂齐佩能(Bacqure)与泰能(Tienam)治疗中性粒细胞缺乏伴发热的疗效及成本。方法:将51例次中性粒细胞缺乏伴发热患儿随机分为齐佩能组29例和泰能组22例,分别选用齐佩能和泰能进行治疗,比较两组临床疗效,并运用药物经济学原理对两种治疗方案进行成本-效果分析。结果:齐佩能与泰能治疗中性粒细胞缺乏伴发热的有效率分别为86.20%和86.36%(P>0.05),成本-效果比(C/E)分别为28.54和42.15;与齐佩能相比,泰能每增加一个单位效果需多花费7 375元。结论:齐佩能与泰能治疗中性粒细胞缺乏伴发热临床疗效比较差异无统计学意义,但齐佩能的成本-效果比低于泰能,有一定的经济学优势。
Objective： To evaluate the clinical efficacy and cost-effectiveness of two kinds of imipenem/cilastatin sodium formulations： Bacqure and Tienam for febrile neutropenia.Methods： Fifty one cases of patients with febrile neutropenia were randomly divided into two groups.Bacqure was used in one group（29 cases） and the other group（22 cases） was treated with Tienam.Evaluate the efficacy of the two groups and use the pharmacological economic principle to analyze the cost-effectiveness of the two groups.Results： The effective rates of Bacqure group and Tienam group in the treatment of febrile neutropenia were 86.20 % and 86.36 %（P0.05） respectively;the cost-effectiveness ratio（C/E） were 28.54 and 42.15.The cost for every one unit increment of effectiveness in Tienam group was 7,375 RMB,which was higher than that in Bacqure group.Conclusions： There was no significant difference between Bacqure group and Tienam group in the clinical efficacy for febrile neutropenia.The cost-effectiveness ratio of Bacqure is superior to that of Tienam and Bacqure is likely to have pharmacoeconomical advantage over Tienam in the treatment of febrile neutropenia.
出处
《儿科药学杂志》
CAS
2013年第1期35-37,共3页
Journal of Pediatric Pharmacy
